Xvivo Perfusion Aktiebolag
Nasdaq Stockholm · LEI 549300G2464FYLS14B41· Fiscal year 2025
Staff cost per employee
Not disclosed
Employees
Not disclosed
Quick read
- Revenue fell 1.2% year over year.
- Operating margin was 10.9% in 2025.
Last 3 years
Revenue
Operating income
See the share price on Google Finance ↗
Investor metrics
2025
- Operating margin
- 10.9%
- Net margin
- 3.1%
- ROE
- 1.2%
- Debt-to-equity
- 12.3%
- Equity ratio
- 89.0%